Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation

European Journal of Clinical Pharmacology

Volumn 60, Issue 10, 2004, Pages 693-701

  Deneer, V H M ^a   Lie A Huen, L ^a   Kingma, J H ^a,b   Proost, J H ^b   Gossen, S A ^b   Stuurman, A ^c   UytdeHaag, G M M ^c   Dunselman, P H J M ^c   Brouwers, J R B J ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c AMPHIA HOSPITAL   (Netherlands)

Author keywords

Atrial fibrillation; Cisapride; Flecainide; Interaction; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CISAPRIDE; FLECAINIDE ACETATE;

ADULT; AGED; ARTICLE; CARDIOVERSION; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OPEN STUDY; PARALLEL DESIGN; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PHARMACODYNAMICS; PRIORITY JOURNAL; PROBABILITY; QRS COMPLEX; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; TABLET FORMULATION;

ADMINISTRATION, ORAL; ANTI-ARRHYTHMIA AGENTS; ANTI-ULCER AGENTS; AREA UNDER CURVE; ATRIAL FIBRILLATION; CHEMISTRY, PHARMACEUTICAL; CISAPRIDE; DRUG COMBINATIONS; ELECTROCARDIOGRAPHY; FEMALE; FLECAINIDE; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; TABLETS;

EID: 12444346819     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0831-3     Document Type: Article

References (31)

1. Suttorp MJ, Kingma JH, Lie-A-Huen L, Mast EG (1989) Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 63:693-696
2. Suttorp MJ, Kingma JH, Jessurun ER, Lie-A-Huen L, Van Hemel NM, Lie KI (1990) The value of class Ic antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. J Am Coll Cardiol 16:1722-1727
3. Margolis B, De Silva RA, Lown B (1980) Episodic drug treatment in the management of paroxysmal arrhythmia. Am J Cardiol 45:621-626
4. Lie-A-Huen L, Kingma JH (1992) Episodic treatment of paroxysmal atrial fibrillation. In: Kingma JH, Van Hemel NM, Lie KI (ed) Atrial fibrillation, a treatable disease? Kluwer, Dordrecht, pp 149-157
5. Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prytowsky EN, Wann LS, Wyse DG (2001) ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences. Eur Heart J 22:1852-1923
6. Hamer AWF, Tanasescu DE, Marks JW, Peter T, Waxman AD, Mandel WJ (1987) Failure of episodic high-dose oral verapamil therapy to convert supraventricular tachycardia: a study of plasma verapamil levels and gastric motility. Am Heart J 114:334-342
7. Salerno DM, Granrud G, Sharkey P, Krejci J, Larson T, Erlien D, Berry D, Hodges M (1986) Pharmacodynamics and side effects of flecainide acetate. Clin Pharmacol Ther 40:101-107
8. Van Gelder IC, Brüggeman J, Crijns HJGM (1998) Current treatment recommendations in antiarrhythmic therapy. Drugs 55:331-346
9. Lie-A-Huen L, Stuurman RM, IJdenberg FN, Kingma JH, Meijer DKF (1989) High performance liquid chromatographic assay of flecainide and its enantiomers in serum. Ther Drug Monit 6:708-712
10. Proost JH (1985) Wagner's exact Loo-Riegelman equation: the need for a criterion to choose between the linear and logarithmic trapezoidal rule. J Pharm Sci 74:793-794
11. Lie-A-Huen L, Proost JH, Kingma JH, Meijer DKF (1990) Absorption kinetics of oral and rectal flecainide in healthy subjects. Eur J Clin Pharmacol 38:595-598
12. Proost JH (1987) Critical evaluation of the determination of bioavailability by numerical deconvolution. Thesis, University of Groningen, The Netherlands
13. Chennavasin P, Brater DC (1982) Aminoglycoside dosage adjustment in renal failure: a hand-held calculator program. Eur J Clin Pharmacol 22:91-94
14. Press WH, Flennery BP, Teukolsky SA, Vetterling WT (1986) Numerical recipes. Cambridge University Press, Cambridge
15. Mentré F, Gomeni R (1995) A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. J Biopharm Stat 5:141-158
16. Bennett JE, Wakefield JC (1996) A comparison of a Bayesian population method with two methods as implemented in commercially available software. J Pharmacokinet Biopharm 24:403-432
17. Baeyens R, Reyntjens A, Verlinden M (1984) Cisapride accelerates gastric emptying and mouth-to-caecum transit of a barium meal. Eur J Clin Pharmacol 27:315-318
18. Kresvsky B, Malmud LS, Maurer AH, Somers MB, Siegel JA, Fisher RS (1987) The effect of oral cisapride on colonic transit. Aliment Pharmacol Ther 1:293-304
19. Deneer VHM, Lie-A-Huen L, Kingma JH, Proost JH, Kelder JC, Brouwers JRBJ (1998) Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. Br J Clin Pharmacol 45:485-490
20. Rowbothan DJ, Milligan K, McHugh P (1991) Effect of single doses of cisapride and ranitidine administered simultaneously on plasma concentrations of cisapride and ranitidine. Br J Anaesth 67:302-305
21. Bateman DN (1986) The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. Eur J Clin Pharmacol 30:205-208
22. Kirch W, Janisch HD, Ohnhaus EE, Van Peer A (1989) Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. Ther Drug Monit 11:411-414
23. Rowbothan DJ, Parnacott S, Nimmo WS (1992) No effect of cisapride on paracetamol absorption after oral simultaneous administration. Eur J Clin Pharmacol 42:235-236
24. World Health Organisation (1998) Cisapride: new contraindications. WHO Drug information 12:236
25. Funck-Brentano C, Becquemont L, Kroemer HK, Buhl K, Knebel NG, Eichelbaum M, Jaillon P (1994) Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance and interaction with amiodarone. Clin Pharmacol Ther 55:256-269
26. Mikus G, Gross AS, Beckmann J, Hertrampf R, Gundert-Remy U, Eichelbaum M (1989) The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. Clin Pharmacol Ther 45:562-576
27. Crijns HJGM, Van Wijk LM, Van Gilst WH, Kingma JH, Van Gelder IC, Lie KI (1988) Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimes. Eur Heart J 9:634-638
28. Padrini R, Piovan D, Busa M, Al-Bunni M, Maiolino P, Ferrari M (1993) Pharmacodynamic variability of flecainide assessed by QRS changes. Clin Pharmacol Ther 53:59-64
29. Boriani G, Capucci A, Strocchi E, Cavilla R, Santarelli A, Biffi M, Maganai B (1993) Flecainide acetate: concentration-response relationships for antiarrhythmic and electrocardiographic effects. Int J Clin Pharm Res XIII:211-219
30. Capucci A, Lenzi T, Boriani G, Trisolino G, Binetti N, Cavazza M, Fontana G, Magnani B (1992) Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 70:69-72
31. Capucci A, Boriani G, Botto GL, Lenzi T, Rubino I, Falcone C, Trisolino G, Della Casa S, Binetti N, Cavazza M, Sanguinetti M, Magnani B (1994) Conversion of recent onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol 74:503-505